HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics

Key Points

• HC Wainwright lowered Hemab Therapeutics’ FY2026 EPS estimate to a loss of $3.19 per share from $3.12, while maintaining a Buy rating and $60 price target.
• Hemab reported quarterly EPS of $(0.80), missing the analyst consensus estimate of $(0.63), underscoring continued near-term losses.
• Despite the earnings miss, analyst sentiment remains favorable: five analysts rate the stock Buy and one rates it Hold, producing a consensus Moderate Buy rating and $51.40 target price.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Free Report) - Equities research analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Hemab Therapeutics in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($3.19) per share for the year, down from their previous estimate of ($3.12). HC Wainwright currently has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Hemab Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Hemab Therapeutics' Q4 2026 earnings at ($0.57) EPS, FY2028 earnings at ($3.62) EPS, FY2029 earnings at ($3.60) EPS and FY2030 earnings at ($2.04) EPS.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17).

Other equities research analysts also recently issued reports about the company. Evercore initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set an "outperform" rating and a $50.00 target price for the company. Wall Street Zen raised Hemab Therapeutics to a "hold" rating in a research note on Saturday, May 9th. Zacks Research upgraded Hemab Therapeutics to a "hold" rating in a report on Wednesday, May 27th. Jefferies Financial Group upped their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a "buy" rating and a $36.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $51.40.

Hemab Therapeutics Stock Up 3.4%

Shares of NASDAQ COAG opened at $53.48 on Thursday. The firm has a market cap of $2.50 billion and a PE ratio of -2.23. The stock has a fifty day moving average of $38.01. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $54.66.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm's stock in a transaction on Tuesday, June 16th. The stock was purchased at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the transaction, the insider owned 6,444,637 shares of the company's stock, valued at $160,987,032.26. The trade was a 0.96% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders bought 72,467 shares of company stock valued at $1,809,595.

Hemab Therapeutics News Roundup

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target from $52 to $60 and maintained a Buy rating. The new target implies additional upside from the stock’s recent $53.48 level, reinforcing investor optimism about Hemab’s development pipeline and long-term prospects. HC Wainwright Forecasts Strong Price Appreciation for Hemab Therapeutics
• Positive Sentiment: The analyst modestly improved several future earnings forecasts. HC Wainwright raised its estimates for fourth-quarter 2026 EPS to $(0.57) from $(0.60), FY2028 EPS to $(3.62) from $(3.63), FY2029 EPS to $(3.60) from $(3.89), and FY2030 EPS to $(2.04) from $(2.44). These revisions suggest expectations for smaller losses in several out-years.
• Neutral Sentiment: Hemab reported second-quarter 2026 financial results and provided a corporate update. The release gives investors a current update on the company’s financial position and operations, but the supplied report does not include specific revenue, cash-balance, or clinical-development details. Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $(3.19) from $(3.12). The downgrade highlights continued near-term cash-burn and loss risk. Hemab also recently reported quarterly EPS of $(0.80), missing the $(0.63) consensus estimate, while the broader consensus expects a $(2.89) loss for the current year.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source